Compound profile
Noopept
Limited human dataAlso known as: GVS-111 · N-phenylacetyl-L-prolylglycine ethyl ester
A synthetic dipeptide developed as a piracetam analogue, sold as a prescription nootropic in Russia for cognitive impairment following stroke and traumatic brain injury. A recurring name in international nootropic-stacking discussions despite thin Western trial data.
Overview
Noopept, also known by the laboratory code GVS-111 and the chemical name N-phenylacetyl-L-prolylglycine ethyl ester, is a small synthetic compound built around a proline-glycine dipeptide backbone. It was synthesized in 1996 at the Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences by a team led by Tatyana Gudasheva, based on the structure of cycloprolylglycine, a naturally occurring neuropeptide the body produces as a metabolite of larger proteins.
It is often grouped with the racetam family of nootropics because it was developed with piracetam as a reference point and is described in the literature as substantially more potent gram for gram, though its chemical structure and dipeptide based design differ meaningfully from piracetam's own pyrrolidone ring structure. The compound is patented in both Russia and the United States, and JSC LEKKO Pharmaceuticals has marketed it as a prescription nootropic in Russia for cognitive impairment associated with stroke and traumatic brain injury.
Outside Russia, noopept occupies a different and more informal lane. In the United States it has circulated as an over the counter dietary supplement ingredient sold by nootropic and supplement retailers, rather than as an FDA approved drug, a status that has drawn periodic regulatory attention given that it is a synthetic pharmaceutical compound with clinical use abroad rather than a naturally occurring dietary ingredient.
Mechanism (plain language)
Proposed to modulate glutamatergic (AMPA/NMDA) signaling and neurotrophic factor pathways; preclinical work also links it to reduced amyloid-beta-related toxicity and tau hyperphosphorylation in cell models.
How it works
Noopept's proposed mechanisms center on glutamate signaling, specifically modulation of AMPA and NMDA receptor activity, two receptor types central to synaptic plasticity, the process by which connections between neurons strengthen with learning and use. Researchers describe it as supporting neurotrophic factor pathways as well, including effects related to nerve growth factor and BDNF, which are broadly involved in neuron survival and the formation of new synaptic connections.
A separate line of preclinical research looks at noopept's effects on amyloid-beta related toxicity and tau hyperphosphorylation in cell models, both processes implicated in Alzheimer's disease pathology, positioning some of the compound's research interest around neuroprotection in aging and neurodegenerative contexts rather than purely acute cognitive enhancement. As its parent compound, cycloprolylglycine, is itself a naturally occurring metabolite with some independent research behind it, part of noopept's proposed advantage is that attaching the phenylacetyl group improves absorption and central nervous system penetration compared with cycloprolylglycine alone, though this comparative pharmacokinetic case rests mainly on the same core group of Russian research publications that developed the compound.
What research suggests
Russian comparative and open-label human studies report improved cognitive test scores in patients with vascular or traumatic mild cognitive impairment, with noopept performing comparably to or better than piracetam at a much lower dose in some comparisons.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Cognitive improvement after stroke
An open prospective study of 60 stroke patients reported significant cognitive improvement after two months of treatment at 20 mg per day, in a clinical, not healthy volunteer, population.
Comparable or superior effect to piracetam at lower doses
A comparative trial in patients with vascular or traumatic brain disease found noopept performed comparably to, or in some measures better than, piracetam, despite being dosed at a much smaller quantity.
Effects across vascular and traumatic cognitive impairment
Human studies span both post-stroke and post-traumatic brain injury cognitive impairment populations, with researchers reporting improvements in standardized cognitive test scores in both groups.
Preclinical neuroprotective signals
Cell model research reports reduced markers of amyloid-beta related toxicity and tau hyperphosphorylation, offering a preclinical rationale for interest in noopept beyond acute cognitive enhancement, though this has not been confirmed in human neurodegenerative disease trials.
Uncertainties & risks
Human trials are concentrated in a small number of Russian research groups and in clinical (post-stroke/TBI) rather than healthy populations; independent replication in healthy users chasing cognitive enhancement is lacking. Not FDA-approved in the US.
Noopept's human trial data is real but comes from a small number of overlapping Russian research groups, and it is concentrated in clinical populations, people recovering from stroke or traumatic brain injury, rather than in healthy adults using it for general cognitive enhancement, which is the primary way it is marketed and used internationally. Independent replication by research groups outside that original circle is sparse, and none of the available human trials meet the scale or independence standards applied to modern FDA drug approvals. It is not FDA approved as a drug in the United States, and its status as a widely sold dietary supplement ingredient there sits somewhat uneasily with its identity as a synthetic pharmaceutical compound with a Russian prescription drug history, an inconsistency that has drawn periodic regulatory attention. Long term safety data in healthy people using it recreationally for cognitive enhancement, at the doses and durations typical of that use, has not been specifically studied, and most of what is known about tolerability comes from the shorter clinical trials in patient populations described above.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.